nodes	percent_of_prediction	percent_of_DWPC	metapath
Agomelatine—Nabumetone—PTGS2—head and neck cancer	0.0257	0.404	CrCbGaD
Agomelatine—Melatonin—CYP1A1—head and neck cancer	0.0164	0.257	CrCbGaD
Agomelatine—Hepatic failure—Hydroxyurea—head and neck cancer	0.0143	0.0307	CcSEcCtD
Agomelatine—Face oedema—Hydroxyurea—head and neck cancer	0.0124	0.0266	CcSEcCtD
Agomelatine—Rash erythematous—Docetaxel—head and neck cancer	0.012	0.0258	CcSEcCtD
Agomelatine—Naproxen—PTGS2—head and neck cancer	0.0119	0.187	CrCbGaD
Agomelatine—Depression—Vinblastine—head and neck cancer	0.0108	0.0232	CcSEcCtD
Agomelatine—Weight increased—Hydroxyurea—head and neck cancer	0.0101	0.0217	CcSEcCtD
Agomelatine—Infestation NOS—Hydroxyurea—head and neck cancer	0.00992	0.0212	CcSEcCtD
Agomelatine—Infestation—Hydroxyurea—head and neck cancer	0.00992	0.0212	CcSEcCtD
Agomelatine—Indomethacin—PTGS2—head and neck cancer	0.00965	0.151	CrCbGaD
Agomelatine—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00938	0.0201	CcSEcCtD
Agomelatine—Phosphatase alkaline increased—Docetaxel—head and neck cancer	0.00921	0.0197	CcSEcCtD
Agomelatine—Hallucination—Hydroxyurea—head and neck cancer	0.00886	0.019	CcSEcCtD
Agomelatine—Irritability—Fluorouracil—head and neck cancer	0.00884	0.0189	CcSEcCtD
Agomelatine—Nasopharyngitis—Fluorouracil—head and neck cancer	0.00829	0.0177	CcSEcCtD
Agomelatine—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.00769	0.0165	CcSEcCtD
Agomelatine—Vertigo—Vinblastine—head and neck cancer	0.00764	0.0164	CcSEcCtD
Agomelatine—Hepatic failure—Docetaxel—head and neck cancer	0.00744	0.0159	CcSEcCtD
Agomelatine—Infestation—Fluorouracil—head and neck cancer	0.00714	0.0153	CcSEcCtD
Agomelatine—Infestation NOS—Fluorouracil—head and neck cancer	0.00714	0.0153	CcSEcCtD
Agomelatine—MTNR1B—GPCR ligand binding—GRP—head and neck cancer	0.0067	0.0143	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR ligand binding—GRP—head and neck cancer	0.0067	0.0143	CbGpPWpGaD
Agomelatine—Migraine—Docetaxel—head and neck cancer	0.00658	0.0141	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00655	0.014	CcSEcCtD
Agomelatine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.00652	0.0139	CbGpPWpGaD
Agomelatine—MTNR1B—Circadian rythm related genes—TYMS—head and neck cancer	0.00647	0.0138	CbGpPWpGaD
Agomelatine—MTNR1A—Circadian rythm related genes—TYMS—head and neck cancer	0.00647	0.0138	CbGpPWpGaD
Agomelatine—Infection—Hydroxyurea—head and neck cancer	0.00629	0.0135	CcSEcCtD
Agomelatine—Paraesthesia—Vinblastine—head and neck cancer	0.00623	0.0133	CcSEcCtD
Agomelatine—Nervous system disorder—Hydroxyurea—head and neck cancer	0.0062	0.0133	CcSEcCtD
Agomelatine—CYP1A2—Estrogen Receptor Pathway—CYP1A1—head and neck cancer	0.00616	0.0131	CbGpPWpGaD
Agomelatine—Skin disorder—Hydroxyurea—head and neck cancer	0.00615	0.0132	CcSEcCtD
Agomelatine—Nasopharyngitis—Docetaxel—head and neck cancer	0.00598	0.0128	CcSEcCtD
Agomelatine—Constipation—Vinblastine—head and neck cancer	0.00593	0.0127	CcSEcCtD
Agomelatine—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00567	0.0121	CcSEcCtD
Agomelatine—Somnolence—Hydroxyurea—head and neck cancer	0.00562	0.012	CcSEcCtD
Agomelatine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.00557	0.0119	CbGpPWpGaD
Agomelatine—Dyspepsia—Hydroxyurea—head and neck cancer	0.00557	0.0119	CcSEcCtD
Agomelatine—HTR2B—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—MAPK3—head and neck cancer	0.00549	0.0117	CbGpPWpGaD
Agomelatine—Abdominal pain—Vinblastine—head and neck cancer	0.00548	0.0117	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00546	0.0117	CcSEcCtD
Agomelatine—Fatigue—Hydroxyurea—head and neck cancer	0.00545	0.0117	CcSEcCtD
Agomelatine—Constipation—Hydroxyurea—head and neck cancer	0.00541	0.0116	CcSEcCtD
Agomelatine—Weight increased—Docetaxel—head and neck cancer	0.00526	0.0113	CcSEcCtD
Agomelatine—Vision blurred—Fluorouracil—head and neck cancer	0.00526	0.0113	CcSEcCtD
Agomelatine—Weight decreased—Docetaxel—head and neck cancer	0.00523	0.0112	CcSEcCtD
Agomelatine—HTR2B—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—MAPK1—head and neck cancer	0.00523	0.0111	CbGpPWpGaD
Agomelatine—CYP1A2—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	0.00521	0.0111	CbGpPWpGaD
Agomelatine—HTR2B—G alpha (q) signalling events—KISS1—head and neck cancer	0.00521	0.0111	CbGpPWpGaD
Agomelatine—Infestation NOS—Docetaxel—head and neck cancer	0.00515	0.011	CcSEcCtD
Agomelatine—Infestation—Docetaxel—head and neck cancer	0.00515	0.011	CcSEcCtD
Agomelatine—CYP2C9—Xenobiotics—CYP1A1—head and neck cancer	0.0051	0.0109	CbGpPWpGaD
Agomelatine—Jaundice—Docetaxel—head and neck cancer	0.00502	0.0108	CcSEcCtD
Agomelatine—CYP1A2—Estrogen metabolism—GSTM1—head and neck cancer	0.00501	0.0107	CbGpPWpGaD
Agomelatine—Asthenia—Vinblastine—head and neck cancer	0.00498	0.0107	CcSEcCtD
Agomelatine—CYP2C9—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.00491	0.0105	CbGpPWpGaD
Agomelatine—Hepatobiliary disease—Docetaxel—head and neck cancer	0.00487	0.0104	CcSEcCtD
Agomelatine—Diarrhoea—Vinblastine—head and neck cancer	0.00475	0.0102	CcSEcCtD
Agomelatine—CYP1A2—Estrogen metabolism—CYP1A1—head and neck cancer	0.00474	0.0101	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1—head and neck cancer	0.00466	0.00992	CbGpPWpGaD
Agomelatine—Hepatitis—Docetaxel—head and neck cancer	0.00463	0.00991	CcSEcCtD
Agomelatine—MTNR1A—GPCR downstream signaling—KISS1—head and neck cancer	0.0046	0.0098	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR downstream signaling—KISS1—head and neck cancer	0.0046	0.0098	CbGpPWpGaD
Agomelatine—Dizziness—Vinblastine—head and neck cancer	0.00459	0.00982	CcSEcCtD
Agomelatine—Connective tissue disorder—Docetaxel—head and neck cancer	0.00455	0.00974	CcSEcCtD
Agomelatine—Asthenia—Hydroxyurea—head and neck cancer	0.00454	0.00972	CcSEcCtD
Agomelatine—Infection—Fluorouracil—head and neck cancer	0.00452	0.00969	CcSEcCtD
Agomelatine—Nervous system disorder—Fluorouracil—head and neck cancer	0.00447	0.00956	CcSEcCtD
Agomelatine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—MAPK3—head and neck cancer	0.00443	0.00944	CbGpPWpGaD
Agomelatine—Vomiting—Vinblastine—head and neck cancer	0.00441	0.00945	CcSEcCtD
Agomelatine—CYP1A2—Xenobiotics—CYP1A1—head and neck cancer	0.00436	0.00929	CbGpPWpGaD
Agomelatine—Headache—Vinblastine—head and neck cancer	0.00435	0.00931	CcSEcCtD
Agomelatine—Diarrhoea—Hydroxyurea—head and neck cancer	0.00433	0.00927	CcSEcCtD
Agomelatine—Eye disorder—Docetaxel—head and neck cancer	0.00432	0.00926	CcSEcCtD
Agomelatine—HTR2B—G alpha (q) signalling events—GRP—head and neck cancer	0.00429	0.00914	CbGpPWpGaD
Agomelatine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—MAPK1—head and neck cancer	0.00422	0.00898	CbGpPWpGaD
Agomelatine—HTR2C—G alpha (q) signalling events—KISS1—head and neck cancer	0.0042	0.00895	CbGpPWpGaD
Agomelatine—HTR2B—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HRAS—head and neck cancer	0.0042	0.00894	CbGpPWpGaD
Agomelatine—CYP1A2—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.00419	0.00894	CbGpPWpGaD
Agomelatine—Dizziness—Hydroxyurea—head and neck cancer	0.00418	0.00896	CcSEcCtD
Agomelatine—MTNR1A—Signaling by GPCR—KISS1—head and neck cancer	0.00417	0.0089	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—KISS1—head and neck cancer	0.00417	0.0089	CbGpPWpGaD
Agomelatine—Nausea—Vinblastine—head and neck cancer	0.00412	0.00882	CcSEcCtD
Agomelatine—Insomnia—Fluorouracil—head and neck cancer	0.00412	0.00882	CcSEcCtD
Agomelatine—Paraesthesia—Fluorouracil—head and neck cancer	0.00409	0.00876	CcSEcCtD
Agomelatine—Mental disorder—Docetaxel—head and neck cancer	0.00405	0.00868	CcSEcCtD
Agomelatine—Somnolence—Fluorouracil—head and neck cancer	0.00405	0.00867	CcSEcCtD
Agomelatine—Vomiting—Hydroxyurea—head and neck cancer	0.00402	0.00861	CcSEcCtD
Agomelatine—Dyspepsia—Fluorouracil—head and neck cancer	0.00401	0.00858	CcSEcCtD
Agomelatine—Headache—Hydroxyurea—head and neck cancer	0.00396	0.00849	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00393	0.00842	CcSEcCtD
Agomelatine—Back pain—Docetaxel—head and neck cancer	0.0039	0.00834	CcSEcCtD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—head and neck cancer	0.00384	0.00817	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR downstream signaling—GRP—head and neck cancer	0.00379	0.00807	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR downstream signaling—GRP—head and neck cancer	0.00379	0.00807	CbGpPWpGaD
Agomelatine—Nausea—Hydroxyurea—head and neck cancer	0.00376	0.00805	CcSEcCtD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1—head and neck cancer	0.00376	0.00801	CbGpPWpGaD
Agomelatine—Urticaria—Fluorouracil—head and neck cancer	0.00362	0.00775	CcSEcCtD
Agomelatine—HTR2C—G alpha (q) signalling events—GRP—head and neck cancer	0.00346	0.00737	CbGpPWpGaD
Agomelatine—HTR2B—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.00345	0.00735	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—GRP—head and neck cancer	0.00344	0.00733	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—GRP—head and neck cancer	0.00344	0.00733	CbGpPWpGaD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00341	0.00729	CcSEcCtD
Agomelatine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HRAS—head and neck cancer	0.00339	0.00721	CbGpPWpGaD
Agomelatine—Dry mouth—Docetaxel—head and neck cancer	0.00335	0.00718	CcSEcCtD
Agomelatine—Infection—Docetaxel—head and neck cancer	0.00327	0.00699	CcSEcCtD
Agomelatine—CYP1A2—Melatonin metabolism and effects—CYP1A1—head and neck cancer	0.00324	0.0069	CbGpPWpGaD
Agomelatine—Nervous system disorder—Docetaxel—head and neck cancer	0.00322	0.0069	CcSEcCtD
Agomelatine—Pruritus—Fluorouracil—head and neck cancer	0.00322	0.0069	CcSEcCtD
Agomelatine—Skin disorder—Docetaxel—head and neck cancer	0.00319	0.00684	CcSEcCtD
Agomelatine—MTNR1A—Circadian rythm related genes—PTEN—head and neck cancer	0.00314	0.0067	CbGpPWpGaD
Agomelatine—MTNR1B—Circadian rythm related genes—PTEN—head and neck cancer	0.00314	0.0067	CbGpPWpGaD
Agomelatine—Diarrhoea—Fluorouracil—head and neck cancer	0.00312	0.00667	CcSEcCtD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—head and neck cancer	0.00309	0.00659	CbGpPWpGaD
Agomelatine—Dizziness—Fluorouracil—head and neck cancer	0.00301	0.00645	CcSEcCtD
Agomelatine—Insomnia—Docetaxel—head and neck cancer	0.00297	0.00637	CcSEcCtD
Agomelatine—Paraesthesia—Docetaxel—head and neck cancer	0.00295	0.00632	CcSEcCtD
Agomelatine—Somnolence—Docetaxel—head and neck cancer	0.00292	0.00626	CcSEcCtD
Agomelatine—Vomiting—Fluorouracil—head and neck cancer	0.0029	0.0062	CcSEcCtD
Agomelatine—Dyspepsia—Docetaxel—head and neck cancer	0.00289	0.0062	CcSEcCtD
Agomelatine—CYP1A2—Estrogen Receptor Pathway—STAT3—head and neck cancer	0.00286	0.00608	CbGpPWpGaD
Agomelatine—Headache—Fluorouracil—head and neck cancer	0.00285	0.00611	CcSEcCtD
Agomelatine—CYP1A2—Phase II conjugation—NAT2—head and neck cancer	0.00285	0.00607	CbGpPWpGaD
Agomelatine—HTR2B—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.00284	0.00605	CbGpPWpGaD
Agomelatine—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00284	0.00608	CcSEcCtD
Agomelatine—Fatigue—Docetaxel—head and neck cancer	0.00283	0.00607	CcSEcCtD
Agomelatine—Constipation—Docetaxel—head and neck cancer	0.00281	0.00602	CcSEcCtD
Agomelatine—HTR2C—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.00278	0.00593	CbGpPWpGaD
Agomelatine—Nausea—Fluorouracil—head and neck cancer	0.00271	0.00579	CcSEcCtD
Agomelatine—Gastrointestinal pain—Docetaxel—head and neck cancer	0.00269	0.00576	CcSEcCtD
Agomelatine—HTR2B—GPCR ligand binding—KISS1—head and neck cancer	0.00263	0.0056	CbGpPWpGaD
Agomelatine—Abdominal pain—Docetaxel—head and neck cancer	0.0026	0.00556	CcSEcCtD
Agomelatine—CYP2C9—Arachidonic acid metabolism—GPX1—head and neck cancer	0.00248	0.00528	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—KISS1—head and neck cancer	0.00247	0.00526	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—KISS1—head and neck cancer	0.00247	0.00526	CbGpPWpGaD
Agomelatine—CYP2C9—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.00245	0.00522	CbGpPWpGaD
Agomelatine—Asthenia—Docetaxel—head and neck cancer	0.00236	0.00505	CcSEcCtD
Agomelatine—Pruritus—Docetaxel—head and neck cancer	0.00233	0.00498	CcSEcCtD
Agomelatine—HTR2C—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.00229	0.00488	CbGpPWpGaD
Agomelatine—Diarrhoea—Docetaxel—head and neck cancer	0.00225	0.00482	CcSEcCtD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—head and neck cancer	0.00224	0.00477	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—head and neck cancer	0.00224	0.00477	CbGpPWpGaD
Agomelatine—CYP1A2—Tryptophan metabolism—CYP1A1—head and neck cancer	0.00224	0.00477	CbGpPWpGaD
Agomelatine—Dizziness—Docetaxel—head and neck cancer	0.00217	0.00465	CcSEcCtD
Agomelatine—HTR2B—GPCR ligand binding—GRP—head and neck cancer	0.00216	0.00461	CbGpPWpGaD
Agomelatine—MTNR1A—Circadian rythm related genes—TP53—head and neck cancer	0.00215	0.00457	CbGpPWpGaD
Agomelatine—MTNR1B—Circadian rythm related genes—TP53—head and neck cancer	0.00215	0.00457	CbGpPWpGaD
Agomelatine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.00212	0.00452	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—KISS1—head and neck cancer	0.00212	0.00451	CbGpPWpGaD
Agomelatine—CYP1A2—Arachidonic acid metabolism—GPX1—head and neck cancer	0.00212	0.00451	CbGpPWpGaD
Agomelatine—CYP1A2—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.0021	0.00446	CbGpPWpGaD
Agomelatine—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.00209	0.00446	CbGpPWpGaD
Agomelatine—Vomiting—Docetaxel—head and neck cancer	0.00209	0.00448	CcSEcCtD
Agomelatine—Headache—Docetaxel—head and neck cancer	0.00206	0.00441	CcSEcCtD
Agomelatine—MTNR1B—Signaling Pathways—GRP—head and neck cancer	0.00203	0.00433	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—GRP—head and neck cancer	0.00203	0.00433	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—STAT6—head and neck cancer	0.00197	0.0042	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—STAT6—head and neck cancer	0.00197	0.0042	CbGpPWpGaD
Agomelatine—Nausea—Docetaxel—head and neck cancer	0.00195	0.00418	CcSEcCtD
Agomelatine—CYP2C9—Biological oxidations—NAT2—head and neck cancer	0.00195	0.00415	CbGpPWpGaD
Agomelatine—CYP2C9—Metapathway biotransformation—NAT2—head and neck cancer	0.00192	0.0041	CbGpPWpGaD
Agomelatine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.00181	0.00386	CbGpPWpGaD
Agomelatine—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.00179	0.00381	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—YAP1—head and neck cancer	0.00174	0.00372	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—YAP1—head and neck cancer	0.00174	0.00372	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—GRP—head and neck cancer	0.00174	0.00372	CbGpPWpGaD
Agomelatine—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.00172	0.00366	CbGpPWpGaD
Agomelatine—CYP1A2—Biological oxidations—NAT2—head and neck cancer	0.00167	0.00355	CbGpPWpGaD
Agomelatine—CYP1A2—Metapathway biotransformation—NAT2—head and neck cancer	0.00164	0.0035	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—KISS1—head and neck cancer	0.00148	0.00316	CbGpPWpGaD
Agomelatine—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.00147	0.00313	CbGpPWpGaD
Agomelatine—CYP2C9—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.00146	0.00311	CbGpPWpGaD
Agomelatine—CYP1A2—Phase II conjugation—GSTM1—head and neck cancer	0.00141	0.003	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—KISS1—head and neck cancer	0.00135	0.00287	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—head and neck cancer	0.00133	0.00284	CbGpPWpGaD
Agomelatine—CYP1A2—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.00125	0.00266	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—head and neck cancer	0.00123	0.00263	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—GRP—head and neck cancer	0.00122	0.0026	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—KISS1—head and neck cancer	0.0012	0.00255	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—GRP—head and neck cancer	0.00111	0.00236	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—KISS1—head and neck cancer	0.00109	0.00232	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—head and neck cancer	0.00105	0.00224	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR downstream signaling—IL2—head and neck cancer	0.00101	0.00215	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR downstream signaling—IL2—head and neck cancer	0.00101	0.00215	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—GRP—head and neck cancer	0.000986	0.0021	CbGpPWpGaD
Agomelatine—CYP2C9—Biological oxidations—GSTM1—head and neck cancer	0.000963	0.00205	CbGpPWpGaD
Agomelatine—CYP2C9—Metapathway biotransformation—GSTM1—head and neck cancer	0.000949	0.00202	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—head and neck cancer	0.000944	0.00201	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—head and neck cancer	0.000944	0.00201	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—head and neck cancer	0.000944	0.00201	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—IL2—head and neck cancer	0.000916	0.00195	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—IL2—head and neck cancer	0.000916	0.00195	CbGpPWpGaD
Agomelatine—CYP2C9—Biological oxidations—CYP1A1—head and neck cancer	0.000913	0.00194	CbGpPWpGaD
Agomelatine—CYP2C9—Metapathway biotransformation—CYP1A1—head and neck cancer	0.0009	0.00192	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—GRP—head and neck cancer	0.000895	0.00191	CbGpPWpGaD
Agomelatine—CYP1A2—Biological oxidations—GSTM1—head and neck cancer	0.000823	0.00175	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—head and neck cancer	0.000822	0.00175	CbGpPWpGaD
Agomelatine—CYP1A2—Metapathway biotransformation—GSTM1—head and neck cancer	0.000811	0.00173	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—UROD—head and neck cancer	0.000803	0.00171	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—KISS1—head and neck cancer	0.000796	0.0017	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—NOTCH1—head and neck cancer	0.000786	0.00168	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—NOTCH1—head and neck cancer	0.000786	0.00168	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—head and neck cancer	0.000782	0.00167	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—head and neck cancer	0.000782	0.00167	CbGpPWpGaD
Agomelatine—CYP1A2—Biological oxidations—CYP1A1—head and neck cancer	0.00078	0.00166	CbGpPWpGaD
Agomelatine—CYP1A2—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000769	0.00164	CbGpPWpGaD
Agomelatine—HTR2B—G alpha (q) signalling events—PIK3CA—head and neck cancer	0.000758	0.00162	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—head and neck cancer	0.000758	0.00162	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—MAPK3—head and neck cancer	0.000736	0.00157	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—MAPK3—head and neck cancer	0.000736	0.00157	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—MAPK1—head and neck cancer	0.000701	0.00149	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—MAPK1—head and neck cancer	0.000701	0.00149	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—EGFR—head and neck cancer	0.000701	0.00149	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—EGFR—head and neck cancer	0.000701	0.00149	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—UROD—head and neck cancer	0.000686	0.00146	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	0.000678	0.00145	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR downstream signaling—PIK3CA—head and neck cancer	0.00067	0.00143	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR downstream signaling—PIK3CA—head and neck cancer	0.00067	0.00143	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—head and neck cancer	0.000663	0.00141	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—GRP—head and neck cancer	0.000656	0.0014	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—KISS1—head and neck cancer	0.000642	0.00137	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—STAT6—head and neck cancer	0.000636	0.00136	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—head and neck cancer	0.000631	0.00134	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—head and neck cancer	0.000631	0.00134	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	0.000628	0.00134	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.000623	0.00133	CbGpPWpGaD
Agomelatine—HTR2C—G alpha (q) signalling events—PIK3CA—head and neck cancer	0.000612	0.0013	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—PIK3CA—head and neck cancer	0.000608	0.0013	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—PIK3CA—head and neck cancer	0.000608	0.0013	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—YAP1—head and neck cancer	0.000563	0.0012	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—HRAS—head and neck cancer	0.000563	0.0012	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—HRAS—head and neck cancer	0.000563	0.0012	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	0.000547	0.00117	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR downstream signaling—AKT1—head and neck cancer	0.000547	0.00117	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR downstream signaling—AKT1—head and neck cancer	0.000547	0.00117	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—IL2—head and neck cancer	0.000541	0.00115	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—IL2—head and neck cancer	0.000541	0.00115	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.000532	0.00113	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—GRP—head and neck cancer	0.000529	0.00113	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CCND1—head and neck cancer	0.000528	0.00112	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CCND1—head and neck cancer	0.000528	0.00112	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—STAT6—head and neck cancer	0.000513	0.00109	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—PTEN—head and neck cancer	0.000509	0.00109	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—PTEN—head and neck cancer	0.000509	0.00109	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	0.000506	0.00108	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—AKT1—head and neck cancer	0.000497	0.00106	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—AKT1—head and neck cancer	0.000497	0.00106	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—VEGFA—head and neck cancer	0.00046	0.00098	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—VEGFA—head and neck cancer	0.00046	0.00098	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—STAT3—head and neck cancer	0.000455	0.00097	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—STAT3—head and neck cancer	0.000455	0.00097	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—YAP1—head and neck cancer	0.000454	0.000968	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—MAPK3—head and neck cancer	0.000435	0.000927	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—MAPK3—head and neck cancer	0.000435	0.000927	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—MAPK1—head and neck cancer	0.000414	0.000882	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—MAPK1—head and neck cancer	0.000414	0.000882	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—EGFR—head and neck cancer	0.000414	0.000882	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—EGFR—head and neck cancer	0.000414	0.000882	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—PIK3CA—head and neck cancer	0.000359	0.000765	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—PIK3CA—head and neck cancer	0.000359	0.000765	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	0.000354	0.000754	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	0.00035	0.000747	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—TP53—head and neck cancer	0.000348	0.000741	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—TP53—head and neck cancer	0.000348	0.000741	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NAT2—head and neck cancer	0.000333	0.00071	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—HRAS—head and neck cancer	0.000332	0.000708	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—HRAS—head and neck cancer	0.000332	0.000708	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—IL2—head and neck cancer	0.000326	0.000694	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	0.000303	0.000645	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	0.000299	0.000638	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—IL2—head and neck cancer	0.000296	0.00063	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—AKT1—head and neck cancer	0.000293	0.000625	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—AKT1—head and neck cancer	0.000293	0.000625	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—DPYD—head and neck cancer	0.000292	0.000623	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NAT2—head and neck cancer	0.000285	0.000607	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—YAP1—head and neck cancer	0.000277	0.000591	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—IL2—head and neck cancer	0.000263	0.00056	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NOTCH1—head and neck cancer	0.000254	0.000541	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—DPYD—head and neck cancer	0.00025	0.000532	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—IL2—head and neck cancer	0.000239	0.000508	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—MAPK3—head and neck cancer	0.000238	0.000507	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—YAP1—head and neck cancer	0.000237	0.000505	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—MAPK1—head and neck cancer	0.000226	0.000482	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—EGFR—head and neck cancer	0.000226	0.000482	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—PIK3CA—head and neck cancer	0.000216	0.000461	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	0.000208	0.000444	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NOTCH1—head and neck cancer	0.000205	0.000436	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PIK3CA—head and neck cancer	0.000196	0.000418	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—MAPK3—head and neck cancer	0.000192	0.000409	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—MAPK1—head and neck cancer	0.000183	0.000389	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—EGFR—head and neck cancer	0.000182	0.000389	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	0.000182	0.000387	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—HRAS—head and neck cancer	0.000182	0.000387	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	0.000178	0.000379	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—AKT1—head and neck cancer	0.000177	0.000376	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IL2—head and neck cancer	0.000175	0.000372	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—PIK3CA—head and neck cancer	0.000174	0.000372	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CCND1—head and neck cancer	0.00017	0.000363	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—TYMS—head and neck cancer	0.000167	0.000355	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GSTM1—head and neck cancer	0.000165	0.000351	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PTEN—head and neck cancer	0.000164	0.00035	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—AKT1—head and neck cancer	0.00016	0.000342	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PIK3CA—head and neck cancer	0.000158	0.000337	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GPX1—head and neck cancer	0.000158	0.000336	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP1A1—head and neck cancer	0.000156	0.000333	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	0.000155	0.000331	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—VEGFA—head and neck cancer	0.000148	0.000316	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—STAT3—head and neck cancer	0.000147	0.000313	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—HRAS—head and neck cancer	0.000147	0.000312	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—AKT1—head and neck cancer	0.000142	0.000304	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—TYMS—head and neck cancer	0.000142	0.000303	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IL2—head and neck cancer	0.000141	0.0003	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTM1—head and neck cancer	0.000141	0.0003	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MAPK3—head and neck cancer	0.00014	0.000299	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CCND1—head and neck cancer	0.000137	0.000293	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GPX1—head and neck cancer	0.000135	0.000287	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MAPK1—head and neck cancer	0.000134	0.000285	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—EGFR—head and neck cancer	0.000134	0.000285	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP1A1—head and neck cancer	0.000133	0.000284	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PTEN—head and neck cancer	0.000133	0.000283	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—AKT1—head and neck cancer	0.000129	0.000276	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	0.000128	0.000273	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—VEGFA—head and neck cancer	0.00012	0.000255	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—STAT3—head and neck cancer	0.000119	0.000253	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CA—head and neck cancer	0.000116	0.000247	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MAPK3—head and neck cancer	0.000113	0.000241	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TP53—head and neck cancer	0.000112	0.000239	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	0.00011	0.000233	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MAPK1—head and neck cancer	0.000108	0.00023	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—EGFR—head and neck cancer	0.000108	0.00023	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—HRAS—head and neck cancer	0.000107	0.000229	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—AKT1—head and neck cancer	9.47e-05	0.000202	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CA—head and neck cancer	9.36e-05	0.000199	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PTGS2—head and neck cancer	9.28e-05	0.000198	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TP53—head and neck cancer	9.05e-05	0.000193	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—HRAS—head and neck cancer	8.66e-05	0.000184	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PTEN—head and neck cancer	8.09e-05	0.000172	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PTGS2—head and neck cancer	7.93e-05	0.000169	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—AKT1—head and neck cancer	7.64e-05	0.000163	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PTEN—head and neck cancer	6.92e-05	0.000147	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CA—head and neck cancer	5.71e-05	0.000122	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CA—head and neck cancer	4.88e-05	0.000104	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—AKT1—head and neck cancer	4.66e-05	9.94e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—AKT1—head and neck cancer	3.99e-05	8.49e-05	CbGpPWpGaD
